91AV

Introduction

Over 350 attendees representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic and healthcare institutions developing immuno-oncology therapies and tools.
 
Over 60 presentations, case studies and panel discussions focussed on the key opportunities and challenges in immuno-oncology, from therapeutic strategies and biomarker development through to clinical research.
 
PLUS, interactive opportunities including:

• Workshop on Accelerating the Treatment & Response Rate of Cancer Immunotherapies
• 6 roundtable discussions on key industry growth areas within immuno-oncology

View Agenda: https://bit.ly/2QbjKSV 

Day One – 21 May 2020

• Discovery of Immuno-Oncology Therapies: Inhibitory Pathway & Cell-Based Approaches
• Translational Immuno-Oncology
• Personalised Therapies for Immuno-Oncology

Day Two – 22 May 2020

• Discovery of Immuno-Oncology Therapies: Antibody and Virus-Based Approaches
• Preclinical Development: Screening, Assays and Modelling in Immuno-Oncology
• Clinical Research & Trials in Immuno- Oncology

Useful links

Speakers

• Celine Adessi Senior Director, Group Head, Oncology, Clinical Safety, F. H, United Kingdom
• Roman Kischel Director, Amgen, United Kingdom
• Andrew Pierce Associate Director, AstraZeneca, United Kingdom
• Mahendra Deonarain Chief Executive and Science Officer, Director of R&D, Antiko, United Kingdom
• Omid Vafa Chief Business Officer, Teneo Bio, United Kingdom
• Jochen Strizker Senior Vice President Immunotherapy, Themis Bioscience, United Kingdom

---

Venue

Novotel London West

Novotel London West, 1 Shortlands, Hammersmith International Ctre, Hammersmith,, London, W6 8DR, United Kingdom

Useful links

Organised by

Contact information

Danielle Dalby, Head of Marketing
Oxford Global
+44 (0)1865 248455
Contact us by email

---